Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daunorubicin and Cytarabine Liposome +/- Pomalidomide in Newly Diagnosed AML With MDS-Related Changes
NCT04802161Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2022
- Primary completion
- Nov 2024
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of pomalidomide in acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Aug 2022; status: active, not recruiting.
02
Drugs
pomalidomide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04802161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04802161.